Veltkamp, R, Korompoki, E, Harvey, KH, Harvey, ER, Fießler, C, Malzahn, U, Rücker, V, Montaner, J, Caso, V, Sibon, I, Ringleb, P, Halse, O, Hügen, K, Ullmann, S, Schuhmann, C, Todd, GP, Haas, K, Palà, E, Debette, S, Lachaize, M et al, D'Aoust, T, Enzinger, C, Ropele, S, Fandler-Höfler, S, Haidegger, M, Wang, Y, Wafa, HA, Cancelloni, V, Mosconi, MG, Lip, GYH, Lane, DA, Haefeli, WE, Foerster, KI, Wurmbach, VS, Nielsen, PB, Hajjar, K, Müller, P, Poli, S, Purrucker, J, Laible, M, D'Anna, L, Silva, Y, de Torres Chacon, R, Martínez-Sánchez, P, Boulanger, M, Norrving, B, Paré, G, Wachter, R, Ntaios, G, Wolfe, CDA, Heuschmann, PU, PRESTIGE-AF Consortium, and Lotto, R (2025) Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. The Lancet, 405 (10482). pp. 927-936. ISSN 0140-6736